[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Boryung Pharmaceutical Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":454},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,40,57,73,89,117,137,162,182,202,227,247,266,287,306,326,350,370,394,415,435],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100625344","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-3-and-br1015-2-under-fed-conditions-100625344",false,"NCT07421414","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions","A Randomized, Open-label, Fed, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-3\" and \"BR1015-2\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Subjects with a body mass index (BMI) of more than 18.0 kg\u002Fm² and less than 30.0 kg\u002Fm² at the screening visit.\n* Subjects who provide written informed consent voluntarily after receiving and understanding sufficient explanation regarding the purpose and procedures of the clinical trial, the characteristics of the investigational product, and the expected adverse events.\n* Subjects who agree to use a highly effective method of contraception, excluding hormonal contraceptives, from the time of signing the written informed consent form until 14 days after the last administration of the investigational product, and who agree not to donate sperm or ova during this period. This requirement applies to the subject and, as applicable, to their spouse or sexual partner in order to prevent pregnancy.\n\nExclusion Criteria:\n\n* Subjects who have taken drugs that induce or inhibit metabolizing enzymes, such as barbiturates, within 30 days prior to the first administration of the investigational product, or who have taken any prescription drugs, over-the-counter drugs (OTC), herbal medicines, or dietary supplements within 10 days prior to the first administration that may interfere with the conduct of the study (however, participation may be allowed considering the pharmacokinetics and pharmacodynamics, including potential interactions with the investigational product and the half-life of concomitant drugs).\n* Subjects with a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs (except for simple appendectomy or hernia surgery).\n* Subjects who have participated in other clinical trials (including bioequivalence studies) and received investigational products within 6 months prior to the first administration of this study. For this criterion, the 6-month period is counted from the last administration date of the investigational product in the previous study.\n* Subjects who are unable to discontinue consumption of foods that may affect the absorption, distribution, metabolism, or excretion of the investigational product (e.g., raw grapefruit, grapefruit juice, or foods containing grapefruit) from 48 hours prior to the first administration of the investigational product until the collection of the last pharmacokinetic blood sample.\n* Subjects who, for reasons other than those specified in the inclusion and exclusion criteria above, are judged by the principal investigator (or a sub-investigator delegated by the principal investigator) to be unsuitable for participation in the clinical trial.\n* Female subjects who are pregnant, suspected of being pregnant, or currently lactating.",true,"ALL","19 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions",[27],"Essential Hypertension","NOT_YET_RECRUITING","2026-02-12",{"date":31,"type":32},"2026-02-19","ACTUAL",{"date":34,"type":21},"2026-04-19",{"date":36,"type":21},"2026-06-17",{"name":38,"class":39},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100625343","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-3-and-br1015-2-under-fasting-conditions-100625343","NCT07421401","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions","A Randomized, Open-label, Fasting, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-3\" and \"BR1015-2\" in Healthy Adult Volunteers",{"count":47,"type":21},58,[24],"The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions",[27],{"date":31,"type":32},{"date":53,"type":21},"2026-04-13",{"date":55,"type":21},"2026-06-11",{"name":38,"class":39},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100625341","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-1-and-br1015-2-under-fasting-conditions-100625341","NCT07421375","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions","A Randomized, Open-label, Fasting, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-1\" and \"BR1015-2\" in Healthy Adult Volunteers",{"count":47,"type":21},[24],"The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions",[27],{"date":31,"type":32},{"date":69,"type":21},"2026-04-02",{"date":71,"type":21},"2026-05-31",{"name":38,"class":39},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100625342","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-1-and-br1015-2-under-fed-conditions-100625342","NCT07421388","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions","A Randomized, Open-label, Fed, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-1\" and \"BR1015-2\" in Healthy Adult Volunteers",{"count":20,"type":21},[24],"The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions",[27],{"date":31,"type":32},{"date":85,"type":21},"2026-04-09",{"date":87,"type":21},"2026-06-07",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100606839","phase-2-a-study-of-bosmolisib-br101801-in-participants-with-rr-ptcl-100606839","NCT07180771","A Study of Bosmolisib (BR101801) in Participants With R\u002FR PTCL.","A Phase II, Single-arm, Multicenter, Open Label Study to Evaluate Efficacy and Safety of BR101801 Monotherapy in Relapsed\u002FRefractory Peripheral T-cell Lymphoma Patients","Key Inclusion Criteria:\n\n1. The ECOG performance status ≤ 2.\n2. Life expectancy more than 3 months.\n3. Patients with relapsed and\u002For refractory to standard therapy or are intolerance to standard therapy diagnosed with 2022 World Health Organization (WHO) classification\n\n   * Peripheral T-cell lymphoma, not otherwise specified\n   * Nodal TFH cell lymphoma, angioimmunoblastic-type\n   * Nodal TFH cell lymphoma, follicular-type\n   * Nodal TFH cell lymphoma, NOS\n4. Patients currently requiring systemic therapy at the investigator's discretion.\n5. Patients with a lesion measuring 1.5 cm or more in its longest transverse diameter, as determined by CT, PET\u002FCT or MRI scans according to the 2014 Lugano criteria.\n\nKey Exclusion Criteria:\n\n1. The presence of overt leptomeningeal or active central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks.\n2. Impaired cardiac function or clinically significant cardiac disease.\n3. Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia\u002Fpneumonitis.\n4. For patients with lymphoma:\n\n   * Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon \\[INF\\], and toxin immunoconjugates) or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment.\n   * Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.\n   * Unconjugated monoclonal antibody therapies \\\u003C 6 weeks before the first dose of study treatment.\n5. Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (\\>20 mg\u002Fday prednisone or equivalent).",{"count":97,"type":21},44,[99],"PHASE2","The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).",[102],"Peripheral T Cell Lymphoma",[104,105,106,107,108],"PTCL","Bosmolisib","BR101801","PI3K inhibitor","DNA-PK","2026-01-27",{"date":111,"type":32},"2026-01-28",{"date":113,"type":21},"2026-02",{"date":115,"type":21},"2027-09",{"name":38,"class":39},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100621668","phase-2-a-study-of-br1400-1-br1400-2-br1400-3-br1400-4-and-br1400-5-in-patients-with-essential-hypertension-100621668","NCT07373613","A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","Inclusion Criteria:\n\n\\\u003CScreening Visit (V1)\\>\n\nPatients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:\n\n* For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP \\\u003C 180 mmHg\n* For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP \\\u003C 180 mmHg\n\nFor patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study.\n\n\\\u003CBaseline Visit (V2)\\>\n\nPatients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:\n\n* For patients without cardiovascular disease: 140 mmHg ≤ MSSBP \\\u003C 180 mmHg\n* For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP \\\u003C 180 mmHg\n\nExclusion Criteria:\n\n* Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2)\n* Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)\n* Patients with shock\n* Patients with orthostatic hypotension accompanied by symptoms",{"count":125,"type":21},330,[99],"The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.",[27],"2026-01-20",{"date":111,"type":32},{"date":132,"type":21},"2026-03-01",{"date":134,"type":21},"2027-02-01",{"name":38,"class":39},1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":136},"100613176","a-study-of-second--and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer-100613176","NCT07263178","A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.","A Multi-center, Prospective, Observational Study to Assess the Treatment Patterns and Prognosis of Second and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer Who Failed First-line Palliative Chemotherapy","Inclusion Criteria:\n\n* Patients who have signed the informed consent after receiving information about the purpose and method of this study.\n* Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.\n* Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).\n* Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.\n\nExclusion Criteria:\n\n* Female patients who are pregnant, have childbearing potential, or are breastfeeding.\n* Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.\n* Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.",{"count":145,"type":21},1000,"OBSERVATIONAL","This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.",[149],"Metastatic Colorectal Cancer",[151,149,152],"Palliative chemotherapy","Observation Study","RECRUITING","2025-11-23",{"date":156,"type":32},"2025-12-04",{"date":158,"type":32},"2025-11-07",{"date":160,"type":21},"2029-12",{"name":38,"class":39},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":136},"100613177","a-study-of-olanzapine-in-participants-with-bipolar-disorder-100613177","NCT07263191","A Study of Olanzapine in Participants With Bipolar Disorder.","A Multicenter, Prospective Observational Study to Evaluate Treatment Patterns and Safety in Patients With Bipolar Disorder Taking Olanzapine","Inclusion Criteria:\n\n* Patients who have signed the informed consent after receiving information about the purpose and method of this study.\n* Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.\n* Patients who understand the contents of the survey and can answer the questions directly.\n\nExclusion Criteria:\n\n* Female patients who are pregnant, have childbearing potential, or are breastfeeding.\n* Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.\n* Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.",{"count":170,"type":21},3000,"This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.",[173],"Bipolar Disorder",[175,176,173],"Olanzapine","Observation study",{"date":156,"type":32},{"date":179,"type":32},"2025-10-30",{"date":115,"type":21},{"name":38,"class":39},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":136},"100517741","observational-study-to-evaluate-the-safety-and-efficacy-of-zepzelca-injection-100517741","NCT06021483","Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection","Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection (Lurbinectedin) in Patients With Metastatic Small Cell Lung Cancer (SCLC) in Real-World Practice","Inclusion Criteria:\n\n* Patients who voluntarily provide written consent for personal information collection and utilization after receiving an explanation about the objective and methods of the study\n* Patients who have received or are scheduled to receive Zepzelca™ inj., according to domestic approval indications\n* Patients with metastatic SCLC who have failed first-line platinum-based chemotherapy\n\nExclusion Criteria:\n\n* Patients with no prior history of platinum-based anticancer chemotherapy for cancer treatment\n* Patients with a history of hypersensitivity reactions to this drug or its components\n* Pregnant, potentially pregnant, or lactating women\n* Patients currently participating in another clinical trial (drug or medical device) or planning to participate in another clinical trial during the study period (except for non-interventional clinical studies or cases where the clinical trial drug administration has ended and only follow-up is remaining)\n* Patients who are judged by the principle Investigator or sub-Investigator to be ineligible to participate in the study.",{"count":190,"type":21},300,"The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.",[193],"SCLC","2025-09-14",{"date":196,"type":32},"2025-09-16",{"date":198,"type":32},"2023-08-16",{"date":200,"type":21},"2025-09",{"name":38,"class":39},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":136},"100590846","phase-4-a-phase-iv-clinical-trial-to-compare-the-efficacy-and-safety-of-metforminsodium-glucose-cotransporter-2-inhibitorsglt2-ithiazolidinedione-tzd-in-patients-with-type-2-diabetes-100590846","NCT06972732","A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes","TELOS","Inclusion Criteria:\n\n* Has voluntarily agreed to participate in this clinical trial.\n* Adults over 19 years of age\n* Diagnosed with type 2 diabetes\n\nExclusion Criteria:\n\n* Has severe renal and liver disorders\n* Has type 1 diabetes\n* Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study\n* Those who are deemed ineligible to participate in the study by the investigator",{"count":211,"type":21},204,[213],"PHASE4","This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.",[216],"Type 2 Diabetes",[218],"type 2 diabetes","2025-09-11",{"date":221,"type":32},"2025-09-15",{"date":223,"type":32},"2025-06-11",{"date":225,"type":21},"2026-10-01",{"name":38,"class":39},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":246},"100579257","phase-2-a-clinical-trial-to-evaluate-the-safety-and-efficacy-of-olanzapine-titration-schedule-in-patients-with-schizophrenia-100579257","NCT06821945","A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia","A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia","Inclusion Criteria:\n\n* Of patients with schizophrenia in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria, who are judged that administration of low dose is more appropriate than initial recommended dose or standard titration dose of olanzapine to consider medical conditions by investigator\n* Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)\n\nExclusion Criteria:\n\n* Patients diagnosed schizophrenia spectrum and other psychotic disorder(e.g. schizoaffective disorder, etc.), bipolar disorder, depressive disorder, etc., in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria at screening visit(Visit 1)\n* Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)",{"count":235,"type":21},120,[99],"The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia",[239],"Schizophrenia",{"date":221,"type":32},{"date":242,"type":32},"2025-05-30",{"date":244,"type":21},"2027-05",{"name":38,"class":39},2,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":136},"100513804","a-study-to-evaluate-the-efficacy-and-safety-of-dapagliflozin-in-patient-with-type-2-diabetes-mellitus-and-hypertension-100513804","NCT05970237","A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension","A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension","Inclusion Criteria:\n\n* Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.\n* Those who voluntarily signed a written personal information agreement to participate in this clinical study.\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)\n* Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)\n* Those who are expected to need insulin prescription during the study period\n* Pregnant women, breast-feeding women",{"count":255,"type":21},9000,"The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension",[258,259],"Diabetes Mellitus","Hypertension",{"date":221,"type":32},{"date":262,"type":32},"2023-07-26",{"date":264,"type":21},"2025-10-21",{"name":38,"class":39},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":273,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":246},"100557410","a-study-to-evaluate-ethanol-induced-symptoms-and-safety-in-breast-cancer-patients-100557410","NCT06537752","A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients","A Multi-center, Prospective, Observational stuDy to Evaluate EThanOl-induced Symptoms and Safety in Breast Cancer Patients witH Neoadjuvant\u002FAdjuvant Chemotherapy Including Non-ethanol Formulation Docetaxel Before and After Surgery","Inclusion Criteria:\n\n* Those who voluntarily signed a written personal information collection and usage agreement after receiving an explanation about the objective and method, etc. of this clinical study.\n* Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable.\n\n  * Those who need neoadjuvant chemotherapy as breast cancer patients\n  * Those who need adjuvant chemotherapy after breast cancer surgery\n* Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Those are diagnosed with other primary cancer that can influence the treatment or prognosis of primary breast cancers.\n* Those are diagnosed with secondary breast cancers.\n* Those with Stage 0\u002F1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.","FEMALE",{"count":275,"type":21},1052,"The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant\u002Fadjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery",[278],"Breast Cancer","2025-09-10",{"date":281,"type":32},"2025-09-12",{"date":283,"type":32},"2024-07-15",{"date":285,"type":21},"2026-10",{"name":38,"class":39},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":136},"100540290","a-study-to-evaluate-the-efficacy-and-safety-of-fixed-dose-combination-of-pitavastatinezetimib-100540290","NCT06314919","A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin\u002FEzetimib","A Multicenter, Prospective, Cohort Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin\u002FEzetimibe Under the Real-World Condition","Inclusion Criteria:\n\n* Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia\n* Those who are judged to need administration of a fixed-dose combination of pitavastatin\u002Fezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe\n\nExclusion Criteria:\n\n* Those who are taking a fixed-dose combination of pitavastatin\u002Fezetimibe at study enrollment\n* Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe\n* Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.",{"count":295,"type":21},8606,"The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin\u002FEzetimibe under the real-world condition",[298,299],"Primary Hypercholesterolemia","Mixed Dyslipidemia",{"date":281,"type":32},{"date":302,"type":32},"2024-03-15",{"date":304,"type":21},"2026-06",{"name":38,"class":39},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":136},"100470991","an-os-to-evaluate-effectiveness-and-safety-of-fixed-dose-combinations-of-fmsaml-or-fmsamlhctz-100470991","NCT05413057","An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS\u002FAML or FMS\u002FAML\u002FHCTZ","A Multicenter, Prospective, Observational Study to Evaluate Effectiveness and Safety of Fixed-dose Combinations of Fimasartan\u002FAmlodipine or Fimasartan\u002FAmlodipine\u002FHydrochlorothiazide in Essential Hypertensive Patients","* Inclusion Criteria:\n\n  1. Patients who voluntarily consent on the informed consent form and understand the study's purpose, methods, and so on\n  2. Males and females over the age of 19\n  3. Patients who have been diagnosed with essential hypertension and plan to be treated with fimasartan\u002Famlodipine or fimasartan\u002Famlodipine\u002Fhydrochlorothiazide\n\n     If the patient is applicable, one of the following;\n     * If the patients have severe hypertension, stage 2 or higher(sit SBP ≥ 160 mmHg or sit DBP ≥ 100 mmHg), or high-risk hypertension (The cardiovascular risk score of the 2018 hypertension treatment guidelines by the Korean Society of Hypertension is applied.) The patients have never been treated with antihypertensive drugs for essential hypertension.\n     * If the patients are on concomitant administration of fimasartan\u002Famlodipin and hydrochlorothiazide for essential hypertension or, If the patients are on concomitant administration of a fimasartan\u002Fhydrochlorothiazide combination and amlodipine for essential hypertension\n     * If the patients have a blood pressure of sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg even though they have been treated with antihypertensive drugs for essential hypertension\n  4. The patients who understand this study and are available to participate in this study until the end of the study period with a cooperative attitude.\n* Exclusion Criteria:\n\n  1. The patients who are suspected of having secondary hypertension or confirmed to have secondary hypertension\n  2. The patients who are contraindicated to taking fimasartan complex according to the drug labelling\n  3. The patients who are currently participation in another clinical trials (Drugs or medical devices) The patients who took an investigational drug within 12 weeks of the enrollment date\n\n     However, the following patients can participate in this study:\n\n     The patients who are currently enrolled in non-interventional clinical studies or who are being followed up on after the administration of investigational drugs has ended.\n  4. The patients who are not suitable for this study by the investigators",{"count":314,"type":21},20000,"The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan\u002Famlodipine or fimasartan\u002Famlodipine\u002Fhydrochlorothiazide, based on fimasartan. (Stage 1).\n\nAlso, this study will evaluate major cardiovascular events, long-term blood pressure control, and the safety by follow-up of those who consent to the extended study for about 2 years (96 weeks).(Stage 2)",[317],"Hypertension,Essential",[319,320],"Fimasartan","Essentail hypertension",{"date":281,"type":32},{"date":323,"type":32},"2022-06-23",{"date":304,"type":21},{"name":38,"class":39},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":136},"100599353","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-safety-between-br3006-and-co-administration-of-br3006a-br3006b-and-br3006c-in-healthy-adult-volunteers-fasting-100599353","NCT07083388","A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fasting)","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\" and \"BR3006C\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Adults aged over 19 at the time of consent\n* Those who are eligible to participate in the clinical trial at the discretion of the principal investigator (or a subinvestigator) through laboratory tests such as hematology tests, blood chemistry tests, serology tests, urine tests, and electrocardiogram (ECG) tests that were planned\u002Fperformed with specification to the investigational product.\n* Those who provided written consent after receiving sufficient explanations and fully understood the objective and details of this clinical trial, the characteristics of the investigational product, and the expected adverse events.\n\nExclusion Criteria:\n\n* Those who have administered investigational products within 6 months from the first dose administration date in another clinical trial (including bioequivalent studies) (The end of study date is based on the last dose administration date.)\n* Those who have undergone gastrointestinal surgeries or have gastrointestinal diseases (except appendectomy or hernia surgery) that may affect the absorption of the investigational products\n* Those who are pregnant, suspected of pregnancy, or nursing",{"count":334,"type":21},52,[24],"This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of \"BR3006\" and co-administration of \"BR3006A\", \"BR3006B,\" and \"BR3006C\" in healthy adult volunteers.",[258],[339,340,341],"Dapagliflozin","Pioglitazone","Metformin HCl","2025-07-16",{"date":344,"type":32},"2025-07-24",{"date":346,"type":32},"2025-07-03",{"date":348,"type":21},"2026-07-03",{"name":38,"class":39},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":136},"100599354","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-safety-between-br3006-and-co-administration-of-br3006a-br3006b-and-br3006c-in-healthy-adult-volunteers-fed-100599354","NCT07083401","A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fed)","An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\" and \"BR3006C\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Adults aged over 19 at the time of consent\n* Those who are eligible to participate in the clinical trial at the discretion of the principal investigator (or a subinvestigator) through laboratory tests such as hematology tests, blood chemistry tests, serology tests, urine tests, and electrocardiogram (ECG) tests that were planned\u002Fperformed with specification to the investigational product.\n* Those who provided written consent after receiving sufficient explanations and fully understood the objective and details of this clinical trial, the characteristics of the investigational product, and the expected adverse events.\n\nExclusion Criteria:\n\n* Those who have administered investigational products within 6 months from the first dose administration date in another clinical trial (including bioequivalent studies) (The end of study date is based on the last dose administration date.)\n* Those who have undergone gastrointestinal surgeries or have gastrointestinal diseases (except appendectomy or hernia surgery) that may affect the absorption of the investigational products\n* Female subjects who are pregnant, suspected of pregnancy, or nursing",{"count":358,"type":21},40,[24],"This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of \"BR3006\" and co-administration of \"BR3006A\", \"BR3006B,\" and \"BR3006C\" in healthy adult volunteers.",[362],"Diabete Mellitus",[339,340,341],{"date":344,"type":32},{"date":366,"type":32},"2025-07-05",{"date":368,"type":21},"2026-07-05",{"name":38,"class":39},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":273,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":136},"100598272","phase-1-a-bioequivalence-study-to-evaluate-pharmacokinetics-and-safety-of-br2022-and-br2022-1-in-patients-with-deleterious-or-suspected-deleterious-germline-brca-mutated-advanced-ovarian-cancer-100598272","NCT07069335","A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer","A Multi-centre, Open-Label, Randomized, Two-Stage, Two-treatment, Two-Period, Multiple-Dose, Crossover Bioequivalence Study to Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Females aged 19 -74 at the time of consent\n2. Those who voluntarily signed the informed consent to participate in this study\n3. Patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been taking stable doses of olaparib for more than 3 months before screening.\n\nExclusion Criteria:\n\n1. Those who have a history of severe hypersensitivity to drugs that include the ingredients of the investigational product or have a history of clinically significant hypersensitivity reactions\n2. Those who have gastrointestinal disorders (e.g., gastroesophageal reflux disease, gastrospasm, gastritis, gastrointestinal ulcers, Crohn's disease, etc.) or have had surgeries (excluding appendectomy or hernia surgery) that may affect the absorption of the investigational products\n3. Those who are pregnant, suspected of pregnancy, or nursing","74 Years",{"count":379,"type":21},24,[24],"This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.",[383],"Ovarian Cancer",[385,383,386],"BRCA-mutated","BR2022","2025-07-07",{"date":342,"type":32},{"date":390,"type":32},"2025-06-17",{"date":392,"type":21},"2026-05-15",{"name":38,"class":39},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":377,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":246},"100582760","phase-1-a-study-to-compare-and-evaluate-the-pharmacokinetic-characteristics-and-the-safety-between-administration-of-br2021-and-br2021-1-100582760","NCT06867497","A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1","A Multi-center, Open-label, Randomized, Two-stage, Two-way Crossover Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1 in Patients With Metastatic Adenocarcinoma of the Pancreas","Inclusion Criteria:\n\n* Those with histologically or cytologically proven metastatic adenocarcinoma of the pancreas\n* Those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using medically recognized methods of contraception (contraceptives administration \\& transplantation or intrauterine device(IUD), sterilization(vasectomy, tubal ligation, etc.), barrier methods (spermicide \\& male condom, combined use of contraceptive diaphragm, sponge or cervical cap)) from the date of the first administration of the investigational products to at least 6 months after the last administration date and disagree to provide their sperm or ovum.\n* Those who spontaneously decide to participate and sign written consent to comply with the subject's precautions after listening to and fully understanding detailed explanation of this clinical trial\n\nExclusion Criteria:\n\n* In the case of a female subject, pregnant woman or those suspected pregnancy or lactating woman.\n* Those who have to administer this study's contraindicated drugs with the investigational product from 2 weeks before the participation until end of this study\n* Those who can't discontinue a diet (ex. raw grapefruit, grapefruit juice or food containing grapefruit, etc.) that may affect the absorption, distribution, metabolism, and excretion of the drug from 48 hours before the first administration date to post study visit(PSV)\n* Those who can't discontinue other drugs except the investigational product of this study that may affect the metabolism and excretion of the drug for the entire study period (However, if necessary, such as treatment of adverse event, it can be administrated according to investigator's judgment)\n* Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 4 weeks before the first administration date (However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) or those whose last administration date of their investigational products of other clinical trials doesn't elapse five times the half-life of their investigational products based on the first administration date of investigational product of this study",{"count":402,"type":21},20,[24],"The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas",[406],"Metastatic Adenocarcinoma of the Pancreas","2025-04-08",{"date":409,"type":32},"2025-04-10",{"date":411,"type":32},"2025-02-24",{"date":413,"type":21},"2025-10-28",{"name":38,"class":39},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":136},"100525767","a-observational-study-to-evaluate-the-efficacy-and-safety-of-pacitol-inj-100525767","NCT06126016","A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.","A Multi-center, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.(Paricalcitol) for Secondary Hyperparathyroidism With Stage 5D Chronic Kidney Disease (CKD 5D) Receiving Hemodialysis","Inclusion Criteria:\n\n* Among hemodialysis patients with secondary hyperparathyroidism due to chronic kidney disease (CKD 5D), those who are scheduled to administer Pacitol Inj. according to the product information.\n* Those who voluntarily signed a written personal information collection and usage agreement to participate in this clinical study after receiving an explanation about the objective and methods of the study.\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Those with a history of hypersensitivity reactions to this drug or its components\n* Those with evidence of vitamin D toxicity\n* Those with hypercalcemia at enrollment\n* Pregnant or lactating women\n* Those with evidence of parathyroid adenoma who is scheduled to undergo parathyroidectomy.\n* Those who have been administered with investigational drugs of other clinical trials within 12 weeks from the baseline(Visit 1).\n* Those who are judged by the principle Investigator or sub-Investigator to be ineligible to participate in the study.",{"count":145,"type":21},"The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis",[425,426],"Chronic Kidney Disease 5D","Secondary Hyperparathyroidism","2024-12-10",{"date":429,"type":32},"2024-12-12",{"date":431,"type":32},"2023-10-19",{"date":433,"type":21},"2026-04",{"name":38,"class":39},{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":246},"100565975","a-study-to-identify-the-risk-of-non-alcoholic-fatty-liver-disease-nafld-in-patients-with-type-2-diabetes-in-clinical-practice-and-to-evaluate-the-clinical-usefulness-of-dapagliflozinpioglitazone-combination-therapy-100565975","NCT06649162","A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin\u002FPioglitazone Combination Therapy","A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin\u002FPioglitazone Combination Therapy","Inclusion Criteria:\n\n* Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin\u002Fpioglitazone at baseline (visit 1)\n* Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.\n\nExclusion Criteria:\n\n* Those who have a history of taking a fixed-dose combination of dapagliflozin\u002Fpioglitazone at baseline (visit 1).\n* Those who are expected to need insulin prescription during the study period.",{"count":443,"type":21},10000,"The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin\u002FPioglitazone combination therapy",[216],"2024-10-17",{"date":448,"type":32},"2024-10-18",{"date":450,"type":32},"2024-09-30",{"date":452,"type":21},"2027-03",{"name":38,"class":39},""]